Therapy of disseminated tumors by adoptive transfer of specifically immune T cells.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Progress in experimental tumor research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000414675PMID 3287447
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory.

  1987cited by this paper
• Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia.

  1986cited by this paper
• Friend virus-specific cytotoxic T lymphocytes recognize both gag and env gene-encoded specificities

  1986cited by this paper
• Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long- term as functional memory T cells

  1986cited by this paper
• Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity.

  1986cited by this paper
• Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.

  1986cited by this paper
• Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells

  1985cited by this paper
• Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen.

  1985cited by this paper
• Ly-1+2- suppressor T cells inhibit the expression of passively transferred antitumor immunity by suppressing the generation of cytolytic T cells.

  1985cited by this paper
• Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth.

  1985cited by this paper
• Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells

  1985cited by this paper
• The murine antitumor immune response and its therapeutic manipulation.

  1984cited by this paper
• Phenotypes associated with tumor rejection mediated by cyclophosphamide and syngeneic tumor‐sensitized t lymphocytes: Potential mechanisms of action

  1984cited by this paper
• Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

  1984cited by this paper
• Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo.

  1984cited by this paper
• The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.

  1984cited by this paper
• Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells.

  1984cited by this paper
• Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations.

  1984cited by this paper
• Combination therapy by using cyclophosphamide and tumor-sensitized lymphocytes: a possible mechanism of action.

  1983cited by this paper
• Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing.

  1983cited by this paper
• Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells

  1983cited by this paper
• Therapy of murine leukemia with monoclonal antibody against a normal differentiation antigen

  1983cited by this paper
• Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus

  1983cited by this paper
• Production of macrophage-activating factor by T lymphocyte clones and correlation with other lymphokine activities.

  1982cited by this paper
• Human tumour antigens defined by cytotoxicity and proliferative responses of cultured lymphoid cells

  1982cited by this paper
• Lysis of tumor biopsy cells by autologous T lymphocytes activated in mixed cultures and propagated with T cell growth factor

  1982cited by this paper
• Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin 2

  1982cited by this paper
• Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2

  1982cited by this paper
• Abnormal migration of T lymphocyte clones.

  1982cited by this paper
• Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease

  1982cited by this paper
• Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes

  1981cited by this paper
• Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens.

  1981cited by this paper
• Immunohistologic evidence for the role of antibody and macrophages in regression of the murine T1699 mammary adenocarcinoma

  1981cited by this paper
• Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2.

  1981cited by this paper
• T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases

  1981cited by this paper
• H-2 restriction of adoptive immunotherapy of advanced tumors.

  1981cited by this paper
• Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes

  1980cited by this paper
• Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia.

  1980cited by this paper
• Specificity of adoptive chemoimmunotherapy of established syngeneic tumors.

  1980cited by this paper
• Characterization of a protein found in cells infected with the spleen focus-forming virus that shares immunological cross-reactivity with the gp70 found in mink cell focus-inducing virus particles

  1979cited by this paper
• Continuous culture of T cells cytotoxic for autologous human leukaemia cells

  1979cited by this paper
• Immunoregulatory circuits among T-cell sets. I. T-helper cells induce other T-cell sets to exert feedback inhibition

  1978cited by this paper
• Immunoregulatory circuits among T-cell sets. Identification of a subpopulation of T-helper cells that induces feedback inhibition

  1978cited by this paper
• Enhanced syngeneic tumor destruction by in vivo inhibition of suppressor T cells using anti-I-J alloantiserum.

  1978cited by this paper
• Immunoregulatory circuits among T-cell sets. II. Physiologic role of feedback inhibition in vivo: absence in NZB mice

  1978cited by this paper
• Genetic control of the immune response to Thy-1 antigens.

  1978cited by this paper
• Autologous leukemia-specific T-cell-mediated lymphocytotoxicity in patients with acute myelogenous leukemia

  1978cited by this paper
• Splenic modifications induced by cyclophosphamide in C3H/He, nude, and "B" mice.

  1977cited by this paper
• Subversion of host defense mechanisms by malignant tumors: an established tumor as a privileged site for bacterial growth

  1977cited by this paper
• Macrophages isolated from regressing Moloney sarcomas are more cytotoxic than those recovered from progressing sarcomas

  1977cited by this paper
• Immunotherapy of lethal metastases by lymphocytes sensitized against tumor cells in vitro.

  1975cited by this paper
• Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.

  1975cited by this paper
• Differential effects of cyclophosphamide on the B and T cell compartments of adult mice.

  1973cited by this paper
• Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice.

  1969cited by this paper

• Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells.

  2018cites this paper
• IL-2 and Beyond in Cancer Immunotherapy

  2018cites this paper
• frequency in the repertoire of normal donors certain HLA-DR alleles and can be recognized by T cells found at low BCR/ABL leukemia oncogene fusion peptides selectively bind to

  2011cites this paper
• Biomarkers in T cell therapy clinical trials

  2011cites this paper
• Priming of immune responses against transporter associated with antigen processing (TAP)‐deficient tumours: tumour direct priming

  2009cites this paper
• Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.

  2008cites this paper
• Immunoprevention of cancer.

  2006cites this paper
• Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: The pattern of in vitro reactivity predicts the in vivo effect on different tumours

  2005cites this paper
• Immunity to melanoma in mice immunized with transfected allogeneic mouse fibroblasts expressing melanoma-associated antigens

  2005cites this paper
• Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells

  2004cites this paper
• Vaccination Is Dependent on Both the Type T Cell Activity After Dendritic Cell

  2000cites this paper
• T Cell Activity After Dendritic Cell Vaccination Is Dependent on Both the Type of Antigen and the Mode of Delivery1

  2000cites this paper
• T cell‐based immunotherapy for cancer: A virtual reality?

  1999cites this paper
• Identification of peptides for immunotherapy of cancer. It is worth the effort.

  1998cites this paper
• Tumor antigens recognized by T lymphocytes

  1997cites this paper
• Human cytotoxic CD8+ T-lymphocyte clones engraft in severe combined immunodeficient (SCID) mice but show diminished function.

  1997cites this paper
• A Phase III randomized study of interleukin‐2 lymphokine‐activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma

  1997cites this paper
• Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV- induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice [published erratum appears in J Exp Med 1996 Sep 1;184(3):1199]

  1996cites this paper
• Tumor Immunotherapy by IL-2 and IL-2 Gene Transfected Cells

  1996cites this paper
• Adjuvant chemo-immunotherapy after curative resection of Stage II and IIIA primary lung cancer.

  1996cites this paper
• BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors.

  1996cites this paper
• The contribution of marker gene studies to hemopoietic stem cell therapies

  1995cites this paper
• Expression of the mage gene family in primary and metastatic human breast cancer: Implications for tumor antigen‐specific immunotherapy

  1995cites this paper
• Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells.

  1995cites this paper
• Tumor antigens recognized by T lymphocytes.

  1994cites this paper
• T-cell based cancer immunotherapy: direct or redirected tumor-cell recognition?

  1994cites this paper
• Psychoneuroimmunology and the course of breast cancer: An overview the impact of psychosocial factors on progression of breast cancer through immune and endocrine mechanisms

  1994cites this paper
• Adoptive immunotherapy with activated peripheral blood lymphocytes.

  1994cites this paper
• T cell subsets involved in immunity against polyoma virus-induced tumors.

  1994cites this paper
• Combination treatment with Interleukin-2 and chemotherapeutic agents

  1993cites this paper
• Interleukin-2 and tumour eradication by cytotoxic T lymphocytes

  1993cites this paper
• Generation of cellular immune responses against a glioma-associated antigen(s).

  1993cites this paper
• T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. I. Significant bispecific lysis of syngeneic colon carcinoma CC531 is critically dependent on prolonged preactivation of effector T-lymphocytes by immobilized anti-T-cell receptor antibody.

  1992cites this paper
• Lessons from T cell responses to virus induced tumours for cancer eradication in general.

  1992cites this paper
• T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides.

  1992cites this paper
• Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes.

  1992cites this paper
• Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.

  1992cites this paper
• Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells.

  1992cites this paper
• Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.

  1992cites this paper
• Cancer immunotherapy: are the results discouraging? Can they be improved?

  1992cites this paper
• The Promise of T Cell Immunotherapy of Cancer

  1991cites this paper
• T-cell immunotherapy of cancer.

  1991cites this paper
• In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes.

  1991cites this paper
• Failure of in vitro-expanded hyperimmune cytotoxic T lymphocytes to affect survival of mouse embryos in vivo.

  1991cites this paper
• Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems.

  1990cites this paper
• Cancer immunology: highlights of the NCI Extramural Immunology Program.

  1990cites this paper
• Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes.

  1990cites this paper
• Enhancement of the effectiveness of Lyt-2+ T-cells for adoptive chemoimmunotherapy by short-term exposure of tumor-bearer spleen cells to polyethylene glycol and/or melphalan.

  1989cites this paper